p.5 抽出テキスト

Recommendation Table 31 — Recommendations for the management of atrial fibrillation in patients receiving anticancer treatment ............................................................................................................ 4297 Recommendation Table 32 — Recommendations for the management of long corrected QT interval and ventricular arrhythmias in patients receiving anticancer treatment ................. 4300 Recommendation Table 33 — Recommendations for the management of arterial hypertension in patients receiving anticancer treatment ..................................................................................... 4302 Recommendation Table 34 — Recommendations for the management of venous thromboembolism in patients receiving anticancer treatment ..................................................................................... 4305 Recommendation Table 35 — Recommendations for venous thromboembolism prophylaxis during anticancer treatment ...... 4306 Recommendation Table 36 — Recommendation for management of peripheral artery disease during anticancer treatment .................. 4307 Recommendation Table 37 — Recommendations for the management of pulmonary hypertension during anticancer treatment ............................................................................................................ 4308 Recommendation Table 38 — Recommendations for the management of pericardial diseases in patients receiving anticancer treatment ..................................................................................... 4309 Recommendation Table 39 — Recommendations for end-of-cancer therapy cardiovascular risk assessment ................... 4312 Recommendation Table 40 — Recommendations for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors ......................................... 4313 Recommendation Table 41 — Recommendations for cardiovascular surveillance in asymptomatic adult cancer survivors 4314 Recommendation Table 42 — Recommendations for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic cancer therapy ............................ 4316 Recommendation Table 43 — Recommendations for adult cancer survivors with coronary artery disease .................................. 4316 Recommendation Table 44 — Recommendations for adult cancer survivors with valvular heart disease ....................................... 4317 Recommendation Table 45 — Recommendation for adult cancer survivors with pericardial complications ............................................... 4318 Recommendation Table 46 — Recommendations for cardiovascular monitoring in cancer survivors during pregnancy 4319 Recommendation Table 47 — Recommendations for cardiovascular assessment and monitoring of pregnant women with cancer ............. 4323 Recommendation Table 48 — Recommendations for carcinoid valvular heart diseases ................................................................................... 4323 Recommendation Table 49 — Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring .............. 4326 Recommendation Table 50 — Recommendations for risk stratification and monitoring for patients with cardiac implantable electronic devices undergoing radiotherapy .................................................... 4330

List of tables

Table 1 Classes of recommendations .................................................... 4237 Table 2 Levels of evidence .......................................................................... 4237 Table 3 Cancer therapy-related cardiovascular toxicity definitions 4243 Table 4 Heart Failure Association–International Cardio-Oncology Society baseline cardiovascular toxicity risk stratification ............... 4246 Table 5 Anthracycline equivalence dose ............................................... 4247 Table 6 Factors that could influence peri-operative risk during cancer surgery and preventive strategies ............................................. 4254 Table 7 Cancer treatments that predispose to acute coronary syndromes .......................................................................................................... 4291 Table 8 Risk factors for drug-induced QT prolongation and torsade de pointes .......................................................................................... 4298 Table 9 Classification of corrected QT interval prolongation induced by cancer drug therapy ............................................................... 4298 Table 10 Risk factors for future cardiovascular disease at the end-of-cancer therapy cardiovascular risk assessment ................... 4310 Table 11 Risk categories for asymptomatic adults who are childhood and adolescent cancer survivors ......................................... 4313 Table 12 Risk categories for asymptomatic adult cancer survivors 4314 Table 13 Management strategies and surgery indications for symptomatic and asymptomatic patients with benign and malignant cardiac tumours .......................................................................... 4321

List of figures

Figure 1 Video 1 Central Illustration: Dynamics of cardiovascular toxicity risk of patients with cancer over their therapy continuum .................................................................................. 4239 Figure 2 Cardio-oncology care pathways ............................................. 4240 Figure 3 Baseline cardiovascular toxicity risk assessment checklist 4241 Figure 4 Dimensions of cancer therapy-related cardiovascular toxicity risk and disease severity .............................................................. 4242 Figure 5 Baseline cardiovascular toxicity risk assessment before anticancer therapy .......................................................................................... 4245 Figure 6 General cardio-oncology approach after Heart Failure Association–International Cardio-Oncology Society cardiovascular toxicity risk assessment ................................................ 4248 Figure 7 Baseline screening recommendations for patients with cancer treated with potentially cardiotoxic drugs ............................ 4250 Figure 8 Recommended transthoracic echocardiography and cardiac magnetic resonance imaging parameters in the evaluation of patients with cancer ............................................................................................... 4252 Figure 9 Primary and secondary cancer therapy-related cardiovascular toxicity prevention .................................................................. 4255 Figure 10 Cardiovascular toxicity monitoring in patients receiving anthracycline chemotherapy ...................................................................... 4258 Figure 11 Cardiovascular toxicity monitoring in patients receiving human epidermal receptor 2-targeted therapies .............................. 4260 Figure 12 Vascular endothelial growth factor inhibitors-related cardiovascular toxicities ............................................................................... 4262 Figure 13 Cardiovascular toxicity monitoring in patients receiving vascular endothelial growth factor inhibitors ..................................... 4263 Figure 14 Breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitor-related cardiovascular toxicities ............ 4265 Figure 15 Second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors surveillance protocol ..................................................................................... 4266 Figure 16 Multiple myeloma drug-related cardiovascular toxicities 4268 Figure 17 Cardiovascular monitoring in patients with multiple myeloma receiving proteasome inhibitors ........................................... 4269 Figure 18 Risk factors for venous thromboembolic events in patients with multiple myeloma ............................................................... 4270 Figure 19 Rapidly accelerated fibrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor-related cardiovascular toxicities ........................................................................................................................ 4272 Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026